Navigation Links
Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Date:11/29/2007

CALGARY, Nov. 29 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced that Dr. Matt Coffey, Chief Scientific Officer of Oncolytics, is scheduled to deliver a presentation on Wednesday, December 5, 2007 entitled "Large Scale Production Process for the Oncolytic Agent REOLYSIN(R) (Human Reovirus)" at the Informa Life Sciences' 3rd Annual Vaccine Production Conference in Cologne, Germany. The conference runs from December 4-5, 2007.
For more information about the conference, please visit

http://www.informa-ls.com/vaccines.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the manufacturing process presented at this conference, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's abilit
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 Dublin ... has announced the addition of the  "Micro Market ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... the fastest-growing segments in the chromatography market. The ... and expected to reach $2.0 billion by 2019, ...
(Date:9/18/2014)... -- About POCT POCT, also ... laboratory. It helps in making fast clinical decisions, ... POCT is gaining popularity due to the increasing ... diabetes, heart disease, and obesity. It is generally ... minimize errors during the diagnosis of patients. POCT ...
(Date:9/18/2014)... September 18, 2014 Texas Governor ... Sharp, Texas A&M Health Science Center CEO Brett ... of Health and Human Services (HHS), State of ... national pandemic influenza vaccine manufacturing facility in Bryan, ... anchor for the Texas A&M Biocorridor – a ...
(Date:9/18/2014)... , Sept. 18, 2014 Research ... "Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, ... report to their offering. The global ... CAGR of 22.7% from 2014 to 2019. Factors such ... growing adoption of companion diagnostics by the pharmaceutical industry, ...
Breaking Biology Technology:Micro Market Monitor : Global Pre-packed Chromatography Columns 2POCT Market in China 2014-2018 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3
... LI-COR Biosciences has released a,new Technical ... the Odyssey Infrared,Imaging System. The E-PAGE 48- ... a high-throughput SDS-PAGE,method for processing protein samples. ... System, up to 96 different proteins samples can ...
... 19 PharmAthene, Inc.,(NYSE Alternext US: PIP), a ... threats, announced today that,it has signed an agreement ... in Israel. , ... combat the risk of,terrorist attacks with biological or ...
... Jazz Pharmaceuticals,Inc. (Nasdaq: JAZZ ) announced that it ... Capital Markets 5th Annual Healthcare,Conference due to the proximity of ... pivotal clinical trial of JZP-6 (sodium oxybate) for,the treatment of ... anticipates that it will release the preliminary top-line data,within the ...
Cached Biology Technology:Technical Note: E-PAGE(TM) 48- and 96-Well Gels on the Odyssey(R) Infrared Imaging System 2PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel 2PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel 3PharmAthene Signs Agreement with Medison Pharma Ltd. to Commercialize and Distribute Biodefense Medical Countermeasures in Israel 4
(Date:9/18/2014)... camouflage: you don,t just blend in, the background shows ... as you might think. Kathryn Feller, from the University ... life stages of many marine species are transparent. However, ... creatures cannot make transparent. Feller explains that the animals ... unit with an opaque pigment to prevent light leaking ...
(Date:9/18/2014)... protective tentacles of host anemones, but new research shows ... across the open ocean. Although the process of long-distance ... the first time that the high level exchange of ... Steve Simpson, Senior Lecturer in Marine Biology and Global ... the Australian Research Council Centre of Excellence for Coral ...
(Date:9/17/2014)... scientists were instrumental in the creation of the Santa ... classify the fire threat potential of the powerful, hot, ... into an inferno. The index was introduced Sept. 17 ... and San Diego Gas and Electric. , The index ... that will be used to help fire agencies and ...
Breaking Biology News(10 mins):Transparent larvae hide opaque eyes behind reflections 2Expedition finds Nemo can travel great distances to connect populations 2Expedition finds Nemo can travel great distances to connect populations 3UCLA scientists play key role in developing new Santa Ana Wildfire Threat Index 2
... of the brain, which scavenge pathogens and damaged neurons, are ... research by Duke neuroscientists. Earlier studies by Staci Bilbo, ... laboratory rats experiencing an infection at an early age have ... their learning and memory. In a study published ...
... Lake City Physicians preparing to deliver a baby look ... whether or not to perform a C- section. But a ... shows that those heart rate patterns may not be a ... lead to unnecessary interventions and higher costs. "We,re trying ...
... a class of theoretical concepts for manipulating the climate ... caused by greenhouse gasses. But its potential effectiveness and ... could help narrow these uncertainties. A team composed of ... and Harvard,s David Keith used modeling to determine the ...
Cached Biology News:Source found for immune system effects on learning, memory 2Source found for immune system effects on learning, memory 3New study finds fetal heart rate not a good indicator of a baby's health 2New study finds fetal heart rate not a good indicator of a baby's health 3Testing geoengineering 2
ANTI DIPHTH TOX A SU...
... Kit (E-22013) provides,researchers with a sensitive ... in solution. This fluorescence-based assay can ... (Figure 1). The assay,measures lysozyme activity ... labeled to such a degree that ...
... m7G(5')ppp(5')G (Cap Analog) is used for the ... in vitro transcription reactions. Substitution of cap ... GTP in an in vitro transcription reaction ... structure into a large fraction of the ...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. It can incubate up to ...
Biology Products: